High grade purification of third-generation HIV-based lentiviral vectors by anion exchange chromatography for experimental gene and stem cell therapy applications. Olgun HB, Tasyurek HM, Sanlioglu AD and Sanlioglu S. Methods Mol Biol. Skin Stem Cellls. 2018 DOI 10.1007/7651_2018_154 Humana Press, New York, NY [Link]
High titer production of HIV-based Lentiviral Vectors in roller bottles for Gene and Cell therapy. Olgun HB, Tasyurek HM, Sanlioglu AD and Sanlioglu S. Methods Mol Biol. Skin Stem Cellls. 2018 DOI 10.1007/7651_2018_150 Humana Press, New York, NY [Link]
HIV-based lentivirus-mediated vasoactive intestinal peptide gene delivery protects against DIO animal model of Type 2 diabetes. Taşyürek M.H., Eksi Y.E., Sanlioglu A.D., Altunbaş H.A., Balci M.K., Griffith T.S., et al., GENE THERAPY, no.0, pp.0-0, 2018 DOI: 10.1038/s41434-018-0011-1 [Link]
Therapeutic potential of lentivirus-mediated glucagon-like peptide-1 (GLP-1) gene therapy for diabetes. Taşyürek M.H., Altunbaş H.A., Balci M.K., Griffith T.S., Sanlioglu S., , HUMAN GENE THERAPY, vol.0, pp.0-0, 2018 doi: 10.1089/hum.2017.180. [Link]
Incretins: their physiology and application in the treatment of diabetes mellitus. Tasyurek HM, Altunbas HA, Balci MK, Sanlioglu S. Diabetes Metab Res Rev. 2014 Jul;30(5):354-71 [PDF]
GLP-1-mediated gene therapy approaches for diabetes treatment. Tasyurek MH, Altunbas HA, Canatan H, Griffith TS, Sanlioglu S. Expert Rev Mol Med. 2014 Mar 26;16:e7 [PDF]
Inkretin Tabanli Tedavi Stratejilerinde Komplikasyon Kaygilari ve Senaryolari. Sanlioglu S. Klinik Tip Bilimleri Dergisi, Clinical Medical Sciences, Nisan 2014 2(1):19-24 [PDF]
Clinical utility of insulin and insulin analogs. Sanlioglu AD, Altunbas HA, Balci MK, Griffith TS, Sanlioglu S. Islets. 2013 Mar-Apr;5(2):67-78. [PDF]
Insulin gene therapy from design to beta cell generation. Sanlioglu AD, Altunbas HA, Balci MK, Griffith TS, Sanlioglu S. Expert Rev Mol Med. 2012 Oct 15;14:e18. [PDF]
Therapeutic potential of VIP vs PACAP in diabetes. Sanlioglu AD, Karacay B, Balci MK, Griffith TS, Sanlioglu S. J Mol Endocrinol. 2012 Oct 12;49(3):R157-67 [PDF]
Tip 1 diyabetli hastalarda insulin tedavisinde ve insulin gen terapisinde guncel gelismeler. Sanlioglu AD, Altunbas HA, Balci MK and Sanlioglu S. Klinik Tip Bilimleri Dergisi, Clinical Medical Sciences, Diyabet ozel sayisi. Nisan 2012 1-5 [PDF]
Tracing of xenogeneic islet graft survival by way of in vivo fluorescence imaging. Kahraman S, Dirice E, Hapil FZ, Ertosun MG, Ozturk S, Griffith TS, Sanlioglu S and Sanlioglu AD. Diabetes Metab Res Rev 2011 27(6):575-83. [PDF]
In Vivo Fluorescence Imaging is Well-Suited for the Monitoring of Adenovirus Directed Transgene Expression in Living Organisms. Kahraman S, Dirice E, Sanlioglu AD, Yoldas B, Bagci H, Erkilic M, Griffith TS and Sanlioglu S. Molecular Imaging and Biology. 2010 Jun; 12 (3):278-85. [PDF]
Adenovirus mediated TRAIL gene (Ad5hTRAIL) delivery into pancreatic islets prolongs normoglycemia in STZ-induced diabetic rats. Dirice E, Sanlioglu AD, Kahraman S, Ozturk S, Balci MK, Omer A, Griffith TS and Sanlioglu S. Human Gene Therapy. Oct 2009, 20(10): 1177-1189. [PDF]
Molecular mechanisms of death ligand-mediated immune modulation: A gene therapy model to prolong islet survival in type 1 diabetes. Sanlioglu AD, Griffith TS, Omer A, Dirice E, Sari R, Altunbas HA, Balci MK, and Sanlioglu S. J Cell Biochem 2008 June 1; 104(3):710-720. [PDF]
High levels of endogenous TRAIL expression correlate with increased cell death in human pancreas. Sanlioglu AD, Dirice E, Elpek O, Korcum AF, Balci MK, Omer A, Griffith TS and Sanlioglu S. Pancreas 2008 May; 36(4):385-393. [PDF]
Gene Therapy of Lung Cancer:
NF-kappaB targeting by way of IKK inhibition sensitizes lung cancer cells to adenovirus delivery of TRAIL. Aydin C, Sanlioglu AD, Bisgin A, Yoldas B, Dertsiz L, Karacay B, Griffith TS and Sanlioglu S. BMC Cancer. 2010, 10:584.
A DcR2 siRNA strategy employing three different siRNA constructs in combination defeats adenovirus transferred TRAIL resistance in lung cancer cells. Aydin C, Sanlioglu AD, Karacay B, Ozbilim G, Dertsiz L, Ozbudak O, Akdis CA and Sanlioglu S. Human Gene Therapy. 2007 Jan; 18: 39-50.
Fundamental Principals of Tumor Necrosis Factor-alpha gene therapy approach and implications for patients with lung carcinoma. Sanlioglu AD, Aydin C, Bozcuk H, Terzioglu E and Sanlioglu S. Lung Cancer. 2004 44: 199-211.
Simultaneous inhibition of Rac1 and IKK Pathways sensitizes lung cancer cells to TNFa mediated apoptosis. Sanlioglu S, Luleci G and Thomas KW. Cancer Gene Therapy. 2001 8(11): 897-905.
Gene Therapy for Prostate Cancer:
Effects of androgen ablation therapy in TRAIL death ligand and its receptor expression in advanced prostate cancer. Koksal IT, Sanlioglu AD, Kutlu O, Sanlioglu S. Urol Int. 2010;84(4):445-51.
DcR2 (TRAIL-R4) siRNA and adenovirus delivery of TRAIL (Ad5hTRAIL) break down in vitro tumorigenic potential of prostate carcinoma cells. Sanlioglu AD, Karacay B, Koksal IT, Griffith TS and Sanlioglu S. Cancer Gene Therapy. 2007 Dec; 14(12):976-984.
Adenovirus mediated IKKbKA expression sensitizes prostate carcinoma cells to TRAIL induced apoptosis. Sanlioglu AD, Koksal IT, Karacay B, Baykara M, Luleci G and Sanlioglu S. Cancer Gene Therapy. 2006 Jan; 13(1): 21-31.
Current progress in adenovirus mediated gene therapy for patients with prostate carcinoma. Sanlioglu AD, Koksal T, Baykara M, Luleci G, Karacay B, Sanlioglu S. Gene Ther Mol Biol. 2003 7: 113-133.
Sanlioglu A.D., Köksal İ.T., Baykara M., Luleci G., Karacay B., Sanlioglu S., "Current progress in adenovirus mediated gene therapy for patients with prostate carcinoma", GENE THERAPY AND MOLECULAR BIOLOGY, pp.113-133, 2003
Gene Therapy of Breast Cancer:
Surface TRAIL decoy receptor-4 expression is correlated with TRAIL resistance in MCF7 breast cancer cells. Sanlioglu AD, Dirice E, Aydin C, Erin E, Koksoy S and Sanlioglu S. BMC Cancer. 2005 25;5(1):54.
Neuroblastoma Targeted Gene Therapy:
Inhibition of the NF-kB Pathway Enhances TRAIL-Mediated Apoptosis in Neuroblastoma Cells. Karacay B, Sanlioglu S, Griffith TS, Sandler A and Bonthius DJ. Cancer Gene Therapy. 2004 Oct; 11(10): 681-690.
TRAIL Death Receptor-4, Decoy Receptor-1 and Decoy Receptor-2 Expression on CD8+ T Cells Correlate with the Disease Severity in Patients with Rheumatoid Arthritis. Bisgin A, Terzioglu E, Aydin C, Yoldas B, Yazisiz V, Balci N, Bagci H, Gorczynski RM, Akdis CA, Sanlioglu S. BMC Musculoskelet Disord. 2010 Aug 27;11:192.
Concurrent gene therapy strategies effectively destroy synoviocytes of patients with rheumatoid arthritis. Terzioglu E, Bisgin A, Sanlioglu AD, Ulker M, Yazisiz V, Tuzuner S, and Sanlioglu S. Rheumatology (Oxford). 2007 May; 46(5): 783-789.
Increased serum sTRAIL levels were correlated with survival in bevacizumab-treated metastatic colon cancer. Bisgin A, Kargi A, Yalcin AD, Aydin C, Ekinci D, Savas B, Sanlioglu S. BMC Cancer. 2012 Feb 7;12:58
Clinical significance of TRAIL and TRAIL receptors in patients with head and neck cancer. Yoldas B, Ozer C, Ozen O, Canpolat T, Dogan I, Griffith TS, Sanlioglu S, Ozluoglu LN. Head Neck. 2011 33(9):1278-84.
Importance of TNF-Related Apoptosis Inducing Ligand in pathogenesis of interstitial cystitis. Kutlu O, Akkaya E, Koksal IT, Bassorgun IC, Ciftcioglu MA, Sanlioglu S, Kukul E. Int Urol Nephrol. 2010 Jun;42(2):393-9.
CTLA-4 gene polymorphism of exon 1(+49 A/G) in Turkish systemic lupus erythematosus patients. Ulker M, Yazisiz V, Sallakci N, Avci AB, Sanlioglu S, Yegin O, Terzioglu E. Int J Immunogenet. 2009 Aug;36(4):245-50.
High TRAIL Death Receptor-4 (DR4) and Decoy Receptor-2 (DcR2) expression correlates with significant cell death in pancreatic ductal adenocarcinoma (PDAC) patients. Sanlioglu AD, Dirice E, Elpek O, Korcum AF, Ozdogan M, Suleymanlar I, Balc? MK, Griffith TS and Sanlioglu S. Pancreas 2009 Mar;38(2):154-60.
Radiotherapy-induced decreases in substance P levels may potentiate melanoma growth. Korcum AF, Sanlioglu S, Aksu G, Tuncel N, Erin N. Molecular Medicine Reports 2009 Mar-Apr; 2(2): 319-326.
TRAIL-R4 decoy receptor gene expression is correlated with high Gleason scores, PSA recurrence and decreased survival in patients with prostate carcinoma. Koksal IT, Sanlioglu AD, Karacay B, Griffith TS and Sanlioglu S. Urologic Oncology 2008 Mar-Apr; 26(2):158-165.
TRAIL death receptor-4 (DR4) expression positively correlates with the tumor grade in breast cancer patients with invasive ductal carcinoma. Sanlioglu AD, Korcum AF, Pestereli E, Erdogan G, Karaveli S, Savas B, Griffith TS and Sanlioglu S. Int J Radiat Oncol Biol Phys. 2007 Nov; 69(3): 716-723.
Differential expression of TRAIL and its receptors in benign and malignant prostate tissues. Sanlioglu AD, Koksal IT, Ciftcioglu MA, Baykara M, Luleci G and Sanlioglu S. Journal of Urology. 2007 Jan; 177(1): 359-364.
Differential PTEN protein expression profiles in superficial versus invasive bladder cancers. Koksal IT, Yasar D, Dirice E., Usta MF, Karauzum S, Luleci G, Baykara M and Sanlioglu S. Urol Int. 2005 75(2): 102-106.
The effect of cetirizine on IFN - gamma and IL10 production in children with allergic rhinitis. Uguz A, Sanlioglu S, Yuzbey S, Coskun M, Yegin O. Turkish Journal of Pediatrics. 2005 47: 111-115.
The assessment of PTEN tumor suppressor gene in combination with Gleason scoring and serum PSA to evaluate progression of prostate carcinoma. Koksal IT., Dirice E, Yasar D, Sanlioglu AD, Gulkesen KH, Ciftcioglu A., Ozes ON, Baykara M, Luleci G and Sanlioglu S. Urol Oncol. 2004 22(4): 307-312.
Gene Therapy of Sepsis
Dajani R, Sanlioglu S, Zhang Y, Li Q, Monick MM, Lazartigues E, Eggleston T, Davisson RL, Hunninghake GH, Engelhardt JF. Pleiotropic Functions of TNF alpha Determine Distinct IKK beta-Dependent Hepatocellular Fates in Response to LPS. Am J Physiol Gastrointest Liver Physiol. 2007 Jan; 292(1): G242-252.
First generation adenovirus vectors shorten survival time in a murine model of sepsis. Sanlioglu, S, Doerschug K, Flaherty, DM, Wilson RL, Yarovinsky TO, Monick MM, Engelhardt JF and Hunninghake GW. J. Immunology. 2002 169: 6539-6545.
Mitochondrial K(ATP) channel openers activate the ERK kinase by an oxidant- dependent mechanism. Samavati L, Monick MM, Sanlioglu S, Buettner GR, Oberley LW, and Hunninghake GW. Am J Physiol Cell Physiol. 2002 Jul;283(1): C273-81.
LPS induces Rac1 dependent reactive oxygen species (ROS) formation and coordinates TNFa secretion through IKK regulation of NFkB. Sanlioglu S, Williams CM, Samavati L, Butler NS, Wang G, McCray PB, Ritchie TC, Hunninghake GW, Zandi E and Engelhardt JF. JBC. 2001 Aug 276(32): 30188-30198.
GPx-1 gene delivery modulates NFkB activation following diverse environmental injuries through a specific subunit of the IKK complex. Li Q, Sanlioglu S, Li S, Ritchie T, Oberley L and Engelhardt JF. Antioxidant and Redox Signaling. 2001 3(3): 415-431.
Gene Therapy for Cardiovascular Diseases
Genetic redox preconditioning differentially modulates AP-1 and NFkappaB responses following cardiac ischemia/reperfusion injury and protects against necrosis and apoptosis. Yang J, Marden JJ, Fan C, Sanlioglu S, Weiss RM, Ritchie TC, Davisson RL, Engelhardt JF. Molecular Therapy. 2003 Mar;7(3): 341-353.
Selective disruption of "late onset" sagittal banding patterns by ectopic expression of engrailed-2 in cerebellar Purkinje cells. Baader SL, Vogel MW, Sanlioglu S, Zhang X, Oberdick J. Journal of Neuroscience. 1999 Jul 1; 19(13): 5370-5379.
Regulation of a Purkinje cell-specific promoter by homeodomain proteins: repression by engrailed-2 vs. synergistic activation by Hoxa5 and Hoxb7. Sanlioglu S, Zhang X, Baader SL, Oberdick J. Journal of Neurobiology. 1998 Sep 15; 36(4): 559-571.
Ectopic overexpression of engrailed-2 in cerebellar Purkinje cells causes restricted cell loss and retarded external germinal layer development at lobule junctions. Sanlioglu S, Baader SL, Berrebi AS, Parker-Thornburg J, Oberdick J. Journal of Neuroscience. 1998 Mar 1; 18(5): 1763-1773.
Functional cloning of candidate genes that regulate Purkinje cell-specific gene expression. Sanlioglu S. and Oberdick J. Progress in Brain Research. 1997 114: 3-19.
Local control of granule cell generation by cerebellar Purkinje cells. Smeyne R, Chu T, Lewin A, Bian F, Sanlioglu S, Kunsch C, Lira SA and Oberdick J. Mol Cell Neuroscience. 1995 6: 230-251.
Isolation and Identification of Novel Human Genes
Structure and genetics of the partially duplicated gene RP located immediately upstream of the complement C4A and C4B genes in the HLA class III region. Shen L, Wu LC, Sanlioglu S, Chen R, Mendoza AR, Dangel A, Carroll MC, Zipf WB, Yung CY. Journal of Biological Chemistry. 1994 269(11): 8466-8476.
Novel approaches to augment adeno-associated virus type-2 endocytosis and transduction. Sanlioglu AD, Karacay B, Benson PK, Engelhardt JF and Sanlioglu S. Virus Research. 2004 Aug; 104(1): 51-59.
Rate Limiting Steps of AAV transduction and Implications for Human Gene Therapy. Sanlioglu S, Monick MM, Luleci G, Hunninghake GW and Engelhardt JF. Review. Current Gene Therapy. 2001 June; 1(2): 137-147.
Endocytosis and Nuclear Trafficking of Adeno-Associated Virus Type-2 is Controlled by Rac1/PI3-kinase Activation. Sanlioglu S, Benson PK, Yang J, Atkinson EM, Reynolds T and Engelhardt JF. Journal of Virology. 2000 Oct; 74(19): 9184-9196.(Cover illustration)
Loss of ATM Function Enhances Recombinant Adeno-Associated Virus Transduction and Integration through Pathways Similar to UV Irradiation. Sanlioglu S, Benson P, Engelhardt JF. Virology. 2000 Mar 1; 268(1): 68-78.
Two Independent Molecular Pathways for Recombinant Adeno-Associated virus genome conversion occur after UV-C and E4orf6 augmentation of transduction. Sanlioglu S, Duan D and Engelhardt JF. Human Gene Therapy. 1999 March 1; 10(4): 591-602.
Cellular Redox State Alters Recombinant Adeno-Associated Virus Transduction Through Tyrosine Phosphatase Pathways. Sanlioglu S and Engelhardt JF. Gene Therapy. 1999 6: 1427-1437.
Formation of adeno-associated virus circular genomes is differentially regulated by adenovirus E4-ORF6 and E2a gene expression. Duan D, Sharma P, Dudus L, Zhang Y, Sanlioglu S, Yan Z, Yue Y, Lester R, Yang J, Fisher KJ, Engelhardt, J.F. Journal of Virology. 1999 73(1): 161-169.
Glucagon-like peptide (GLP)-1 is an incretin hormone with several antidiabetic functions including stimulation of glucose-dependent insulin secretion, increase in insulin gene expression and beta-cell survival... Read more
Therapies targeting the action of incretin hormones have been under close scrutiny in recent years. The incretin effect has been defined as postprandial enhancement of insulin secretion by gut-derived factors. Likewise,incretin
mimetics and incretin effect amplifiers are the two different incretin-based treatment strategies developed for the treatment of diabetes...Read more
Due to the metabolic variability among individuals, optimum blood glucose management is a formidable task to accomplish despite the presence of novel insulin analogs.In this article,
we present a recent update on insulin analog structure and function with an overview of the evidence on the various
insulin regimens clinically used to treat diabetes....Read more
deficiency is the main sequel of type-1 diabetes (T1D), transfer of the insulin
gene-by-gene therapy is becoming an attractive treatment modality even
though T1D is not caused by a single genetic defect...
Type 2 diabetes (T2D) is characterized by chronic insulin resistance and a progressive decline in beta-cell function.
Although rigorous glucose control can reduce morbidity and mortality associated with diabetes, achieving optimal longterm
glycemic control remains to be accomplished in many diabetic patients... Read more
Type 1 diabetes results from the T cell-mediated destruction of pancreatic beta cells. Islet transplantation
has recently become a potential therapeutic approach for patients with type 1 diabetes. However, islet-graft failure
appears to be a challenging issue to overcome... Read more
Type 1 diabetes (T1D), characterized by permanent destruction of insulin-producing beta cells, is lethal unless
conventional exogenous insulin therapy or whole-organ transplantation is employed. Although pancreatic islet
transplantation is a safer and less invasive method compared with whole-organ transplant surgery, its treatment
efficacy has been limited by islet graft malfunction and graft failure... Read more
High levels of decoy receptor 2 (DcR2; TRAIL-R4) expression are correlated with TRAIL resistance in prostate cancer cells. In
addition, upregulation of TRAIL death receptor (DR4 and DR5) expression, either by ionizing radiation or chemotherapy, can
sensitize cancer cells to TRAIL...Read more
While the presence of TRAIL death receptors were necessary for the induction of cell death, high levels of TRAIL-R4 decoy receptor
expression on surface were correlated with TRAIL resistance. A DcR2 siRNA approach in combination with Ad5hTRAIL infection eliminated
apoptosis-resistant RA synovial fibroblasts....Read more
Tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) selectively induces apoptosis in cancer
cells but not in normal cells. However, studies have indicated that more than half of human tumors exhibit
TRAIL resistance. Although the mechanism of TRAIL resistance is not understood, it represents a barrier
to any TRAIL-mediated gene therapy approach. In addition, no correlation between TRAIL receptor
(TRAIL-R) expression profile and TRAIL resistance has been demonstrated in cancer cells...
Despite the fact that tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) can selectively induce apoptosis in cancer
cells, TRAIL resistance in cancer cells has challenged the use of TRAIL as a therapeutic agent. First, prostate carcinoma cell lines
(DU145, LNCaP and PC3) were screened for sensitivity to adenovirus delivery of TRAIL (Ad5hTRAIL)...
Apoptosis, known as programmed cell death, is defined as a cell’s preferred
form of death under hectic conditions through genetically conserved and complex
pathways. There is a decisive balance between stimulatory and inhibitory signaling
pathways to maintain homeostasis in cells.... Read more